A recent evidence demonstrated that not all TP53 mutations are equal: non-disruptive TP53 mutations (those preserving some functional properties of the protein) represents an independent prognostic factor of shorter survival in advanced NSCLC (13.3 versus 24.6 months; HR=2.08; p < 0.001) [29]. The gene discussed is TP53; the disease is non-small cell lung carcinoma.